Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic Efficiency of 68Ga-FAPI PET/CT
NCT05034146Recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Feb 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga-FAPI in malignant neoplasm, sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: The diagnostic sensitivity and specificity of 68Ga-FAPI PET/CT in the staging of malignant tumors at 3 years. Started Feb 2021; status: recruiting.
02
Drugs
68Ga-FAPI
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT05034146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05034146.